The LPS2 mutation in TRIF is atheroprotective in hyperlipidemic low density lipoprotein receptor knockout mice

Innate Immunity

Volumn 19, Issue 1, 2013, Pages 20-29

  Richards, M Rachel ^a   Black, Audrey S ^a   Bonnet, David J ^a   Barish, Grant D ^b   Woo, Connie W ^c   Tabas, Ira ^c   Curtiss, Linda K ^a   Tobias, Peter S ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

atherosclerosis; inflammation; murine models; MyD88; TLR3; TRIF

Indexed keywords

LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN RECEPTOR; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; AORTA SINUS; ARTICLE; ATHEROGENIC DIET; CONTROLLED STUDY; CYTOKINE RELEASE; GENE; GENE MUTATION; HEART PROTECTION; HEART VALVE; HYPERLIPIDEMIA; INFLAMMATION; LPS2 GENE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANIMALS; AORTA; ATHEROSCLEROSIS; CORONARY VESSELS; CYTOKINES; DIET, ATHEROGENIC; HYPERLIPIDEMIAS; LIPOPROTEINS, LDL; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, MUTANT STRAINS; MUTATION; MYELOID DIFFERENTIATION FACTOR 88; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 3;

MURINAE; MUS;

EID: 84872376537     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425912447130     Document Type: Article

References (31)

1. Minino AM, Xu J, Kochanek KD, Tejada-Vera B. Death in the United States. NCHS Data Brief. 2009 ; 26: 1-8
2. Curtiss LK, Tobias PS. The toll of Toll-like receptors, especially toll-like receptor 2, on murine atherosclerosis. Curr Drug Targets. 2007 ; 8: 1230-1238
3. Frantz S, Ertl G, Bauersachs J. Mechanisms of disease: Toll-like receptors in cardiovascular disease. Cardiovasc Med. 2007 ; 4: 444-454
4. Edfeldt K, Swedenborg J, Hansson GK, et al. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation. 2002 ; 105: 1158-1161
5. Xu XH, Shah PK, Faure E, et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation. 2001 ; 104: 3103-3108
6. Hirschfeld M, Ma Y, Weis JH, et al. Cutting edge: Repurification of lipopolysaccharide eliminates signaling through both human and murine Toll-like receptor 2. J Immunol. 2000 ; 165: 618-622
7. Lehr HA, Sagban TA, Ihling C, et al. Immunopathogenesis of atherosclerosis: endotoxin accelerates atherosclerosis in rabbits on hypercholesterolemic diet. Circulation. 2001 ; 104: 914-920
8. Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by Toll-like Receptor 2. J Clin Invest. 2005 ; 115: 3149-3156
9. Michelsen KS, Wong MH, Shah PK, et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA. 2004 ; 101: 10679-10684
10. Paigen B. Genetics of responsiveness to high-fat and high-cholesterol diets in the mouse. Am J Clin Nutr. 1995 ; 62: 458S - 462S
11. Higashimori M, Tatro JB, Moore KJ, et al. Role of Toll-like receptor 4 in intimal foam cell accumulation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2011 ; 31: 50-57
12. Dunzendorfer S, Lee HK, Soldau K, et al. Toll-like receptor 4 functions intracellularly in human coronary artery endothelial cells: roles of LBP and sCD14 in mediating LPS-responses. FASEB J. 2004 ; 18: 1117-1119
13. Lloyd-Jones KL, Kelly MM, Kubes P. Varying importance of soluble and membrane CD14 in endothelial detection of lipopolysaccharide. J Immunol. 2008 ; 181: 1446-1453
14. Baiersdörfer M, Schwarz M, Seehafer K, et al. Toll-like receptor 3 mediates expression of clusterin/apolipoprotein J in vascular smooth muscle cells stimulated with RNA released from necrotic cells. Exp Cell Res. 2010 ; 316: 3489-3500
15. Hoebe K, Du X, Goode J, Mann N, et al. Lps2: a new locus required for responses to lipopolysaccharide, revealed by germline mutagenesis and phenotypic screening. J Endotoxin Res. 2003 ; 9: 250-255
16. Bjorkbacka H, Kunjathoor VV, Moore KJ, et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med. 2004 ; 10: 416-421
17. Lichtnekert J, Vielhauer V, Zecher D, et al. Trif is not required for immune complex glomerulonephritis: dying cells activate mesangial cells via Tlr2/Myd88 rather than Tlr3/Trif. Am J Physiol Renal Physiol. 2009 ; 296: F867 - F874
18. Van Noort JM, Bsibsi M Progress in Brain Research Neurotherapy: Progress in Restorative Neuroscience and Neurology. Joost Verhaagen EMH, ed. Amsterdam: Elsevier ; 2009: 139-148.
19. Smith KD. Toll-like receptors in kidney disease. Curr Opin Nephrol Hypertens. 2009 ; 18: 189-196
20. Mkaddem SB, Bens M, Vandewalle A. Differential activation of Toll-like receptor-mediated apoptosis induced by hypoxia. Oncotarget. 2010 ; 1: 741-750
21. Kono DH, Haraldsson MK, Lawson BR, et al. Endosomal TLR signaling is required for anti-nucleic acid and rheumatoid factor autoantibodies in lupus. Proc Natl Acad Sci USA. 2009 ; 106: 12061-12066
22. Curtiss LK, Tobias PS. Emerging role of Toll-like receptors in atherosclerosis. J Lipid Res. 2009 ; 50: S340 - S345
23. Miller YI, Viriyakosol S, Binder CJ, et al. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem. 2003 ; 278: 1561-1568
24. Stewart CR, Stuart LM, Wilkinson K, et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol. 2010 ; 11: 155-161
25. Seimon TA, Nadolski MJ, Liao X, et al. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab. 2010 ; 12: 467-482
26. Alexopoulou L, Holt AC, Medzhitov R, et al. Recognition of double-stranded RNA and activation of NF-kappaB by toll-like receptor 3. Nature. 2001 ; 413: 732-738
27. Schiller NK, Kubo N, Boisvert WA, et al. Effect of γ-irradiation and bone marrow transplantation on atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2001 ; 21: 1674-1680
28. Schiller NK, Black AS, Bradshaw GP, et al. Participation of macrophages in atherosclerotic lesion morphology in LDLr-/- mice. J Lipid Res. 2004 ; 45: 1398-1409
29. Yamamoto M, Sato S, Hemmi H, et al. Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. Science. 2003 ; 301: 640-643
30. Cole JE, Navin TJ, Cross AJ, et al. Unexpected protective role for Toll-like receptor 3 in the arterial wall. Proc Natl Acad Sci USA. 2011 ; 108: 2372-2377
31. Zimmer S, Steinmetz M, Asdonk T, et al. Activation of endothelial toll-like receptor 3 impairs endothelial function. Circ Res. 2011 ; 108: 1358-1366